AIMS: To study the contribution of epidermal growth factor receptor variant III (EGFRvIII) to glioblastoma multiforme (GBM) stemness and gefitinib resistance. METHODS: CD133(+) and CD133(-) cells were separated from EGFRvIII(+) clinical specimens of three patients with newly diagnosed GBM. Then, RT-PCR was performed to evaluate EGFRvIII and EGFR expression in CD133(+) and CD133(-) cells. The tumorigenicity and stemness of CD133(+) cells was verified by intracranial implantation of 5 × 10(3) cells into immunodeficient NOD/SCID mice. Finally, cells were evaluated for their sensitivity to EGFR tyrosine kinase inhibition by gefitinib. RESULTS: RT-PCR results showed that the sorted CD133(+) cells expressed EGFRvIII exclusively, while the CD133(-) cells expressed both EGFRvIII and EGFR. At 6-8 weeks postimplantation, CD133(+) /EGFRvIII(+) /EGFR(-) cells formed intracranial tumors. Cell counting kit-8 results showed that the IC50 values of the three isolated EGFRvIII(+) cell lines treated with gefitinib were 14.44, 16.00, and 14.66 μM, respectively, whereas the IC50 value of an isolated EGFRvIII(-) cell line was 8.57 μM. CONCLUSIONS: EGFRvIII contributes to the stemness of cancer stem cells through coexpression with CD133 in GBMs. Furthermore, CD133(+) /EGFRvIII(+) /EGFR(-) cells have the ability to initiate tumor formation and may contribute to gefitinib resistance.
AIMS: To study the contribution of epidermal growth factor receptor variant III (EGFRvIII) to glioblastoma multiforme (GBM) stemness and gefitinib resistance. METHODS:CD133(+) and CD133(-) cells were separated from EGFRvIII(+) clinical specimens of three patients with newly diagnosed GBM. Then, RT-PCR was performed to evaluate EGFRvIII and EGFR expression in CD133(+) and CD133(-) cells. The tumorigenicity and stemness of CD133(+) cells was verified by intracranial implantation of 5 × 10(3) cells into immunodeficient NOD/SCIDmice. Finally, cells were evaluated for their sensitivity to EGFR tyrosine kinase inhibition by gefitinib. RESULTS: RT-PCR results showed that the sorted CD133(+) cells expressed EGFRvIII exclusively, while the CD133(-) cells expressed both EGFRvIII and EGFR. At 6-8 weeks postimplantation, CD133(+) /EGFRvIII(+) /EGFR(-) cells formed intracranial tumors. Cell counting kit-8 results showed that the IC50 values of the three isolated EGFRvIII(+) cell lines treated with gefitinib were 14.44, 16.00, and 14.66 μM, respectively, whereas the IC50 value of an isolated EGFRvIII(-) cell line was 8.57 μM. CONCLUSIONS: EGFRvIII contributes to the stemness of cancer stem cells through coexpression with CD133 in GBMs. Furthermore, CD133(+) /EGFRvIII(+) /EGFR(-) cells have the ability to initiate tumor formation and may contribute to gefitinib resistance.
Authors: F Ciardiello; R Caputo; R Bianco; V Damiano; G Fontanini; S Cuccato; S De Placido; A R Bianco; G Tortora Journal: Clin Cancer Res Date: 2001-05 Impact factor: 12.531
Authors: Guido Lammering; Theodore H Hewit; Kristoffer Valerie; Joseph N Contessa; George P Amorino; Paul Dent; Rupert K Schmidt-Ullrich Journal: Oncogene Date: 2003-08-28 Impact factor: 9.867
Authors: Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke Journal: Proc Natl Acad Sci U S A Date: 2003-03-10 Impact factor: 11.205
Authors: Amy B Heimberger; Chris A Learn; Gary E Archer; Roger E McLendon; Tracy A Chewning; Frank L Tuck; John B Pracyk; Allan H Friedman; Henry S Friedman; Darell D Bigner; John H Sampson Journal: Clin Cancer Res Date: 2002-11 Impact factor: 12.531
Authors: Chris A Learn; Tristan L Hartzell; Carol J Wikstrand; Gary E Archer; Jeremy N Rich; Allan H Friedman; Henry S Friedman; Darell D Bigner; John H Sampson Journal: Clin Cancer Res Date: 2004-05-01 Impact factor: 12.531
Authors: Hui K Gan; Martin van den Bent; Andrew B Lassman; David A Reardon; Andrew M Scott Journal: Nat Rev Clin Oncol Date: 2017-07-04 Impact factor: 66.675
Authors: Barry Jutten; Tom G Keulers; Hanneke J M Peeters; Marco B E Schaaf; Kim G M Savelkouls; Inge Compter; Ruud Clarijs; Olaf E M G Schijns; Linda Ackermans; Onno P M Teernstra; Marijke I Zonneveld; Resi M E Colaris; Ludwig Dubois; Marc A Vooijs; Johan Bussink; Julio Sotelo; Jan Theys; Guido Lammering; Kasper M A Rouschop Journal: Autophagy Date: 2018-01-29 Impact factor: 16.016